Nuclera appoints William J. Kullback as Non-Executive Director
- Appointment of leading financial executive supports continued commercial development
- Current CFO at Telesis Bio, former CFO of BioLegend Inc.
Cambridge, UK: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the appointment of William J. Kullback to its Board of Directors as a Non-Executive Director (NED).
Bill is a seasoned executive bringing extensive financial experience from large life science tool manufacturers to Nuclera’s leadership team. He joins the board at a crucial time for Nuclera as the company continues its global commercial expansion strategy following a successful $75 million series C close1.
Dr Michael Chen, CEO and co-founder, Nuclera, commented: “I am pleased to welcome Bill to the Nuclera board. His distinguished career and financial expertise will be instrumental as we push forward with our growth strategy in line with our commercial goals.” He added: “Bill’s experience will be invaluable to Nuclera as we scale to address current challenges in protein production by bringing eProtein Discovery to even more researchers.”
Since August 2023, Bill has held the position of CFO at Telesis Bio, a company specializing in automated synthesis technology for therapeutic discovery, during which time he oversaw the restructuring of operational expenses resulting in a ~70% decrease. He brings over 30 years of experience as a CFO, focusing on financial and manufacturing operations, mergers and acquisitions, and public markets across multiple publicly traded companies. Bill previously served as CFO at BioLegend Inc., a worldwide provider of antibodies and life science reagents, where he helped manage the company’s $5.25 billion sale to NYSE listed Revvity (previously PerkinElmer), the largest acquisition in Revvity’s history.
Bill also negotiated and closed acquisitions and investments whilst CFO at NASDAQ listed medical device company, Lombard Medical, prior to its acquisition by Shanghai-based MicroPort Scientific Corporation. He has also held senior financial positions at a range of medical device and life science tools businesses during his career. Bill earned both his MBA and bachelor’s degree from the State University of New York at Buffalo.
Bill Kullback, Non-Executive Board Director, Nuclera, added: “Nuclera’s eProtein Discovery has the potential to transform drug discovery workflows. The Company is at an exciting stage as it expands globally and I am looking forward to working with the team to support the Company’s growth and drive success at this pivotal stage in Nuclera’s development.”
For more information about Nuclera’s eProtein Discovery system, please visit: https://www.nuclera.com/system/
ENDS
 |
|
| Dr Michael Chen, CEO and co-founder, Nuclera | William Kullback, NED, Nuclera |
About Nuclera www.nuclera.com
Nuclera’s mission is to accelerate discovery by enabling rapid, easy access to functional proteins essential for drug discovery research. The Company’s eProtein Discovery™ benchtop system accelerates protein expression and purification optimization in research labs.
Applying digital microfluidics alongside in situ protein detection assays and cell-free protein synthesis, eProtein Discovery enables rapid, scalable access to high-quality proteins, supporting both cell-free and cell-based expression methods. The system significantly reduces time and cost of these processes by automating construct screening, protein scale-up, and producing purified proteins for downstream functional testing in under 48 hours. The system accelerates workflows, achieving results in days rather than the months required by traditional cell-based methods.
Founded in 2013, Nuclera’s offices are located in Cambridge (UK) and Boston (US).
